JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article

J Thorac Cardiovasc Surg 2007;133:86-87
© 2007 The American Association for Thoracic Surgery

General Thoracic Surgery

Discussion

The first 20% of the full text of this article appears below.

Dr Michael Weyant (Denver, Colo). Dr Hammoud, congratulations on your article. I enjoyed reading it, and I appreciate you sending it to me well ahead of the date of this meeting.

You and your coauthors have found a unique biomarker identifying and isolating malignant cells in esophageal tissue. I think findings such as these are important not only because of the ability to mark a cell but also because they can eventually provide some insight into the biology of the cancer cell itself. You also were able to show us a method that is applicable immediately globally to all pathologists, and I think that is important. But I have a few questions for you.

First, given that a pathologist on a routine hematoxylin and eosin stain can identify a cancer cell on the basis of its nuclear morphology, and you have basically to have the presence of the cancer cell to identify it, how is your technique an actual improvement over those already known methods?

Dr Hammoud. I alluded to this earlier. I think a lot of times the differentiation between high-grade dysplasia and invasive carcinoma is difficult and is pathologist dependent. I think the greatest utility right now of having this antibody is in exactly those scenarios. I agree wholeheartedly that you don’t need this antibody to diagnose cancer, at least not on a biopsy or a tissue specimen, but I think in those difficult cases it . . . [Full Text of this Article]


Related Article

A novel biomarker for the detection of esophageal adenocarcinoma
Zane T. Hammoud, Sunil Badve, Romil Saxena, Kenneth A. Kesler, Karen Rieger, Linda H. Malkas, and Robert J. Hickey
J. Thorac. Cardiovasc. Surg. 2007 133: 82-87. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The American Association for Thoracic Surgery.